Catalyst MedTech Aims to Reshape Nuclear Imaging with New Tech, Full-Service Model

PITTSBURGH, PA – May 26, 2026 – Catalyst MedTech is making a bold play to redefine its role in the nuclear medicine landscape, moving from a leading solutions provider to an end-to-end industry partner. The company arrived at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 annual meeting in Los Angeles with a series of major announcements, unveiling an expanded imaging portfolio, a comprehensive modernization strategy, and a long-term vision built on its recent acquisition of OEM manufacturer X3D.

The strategic pivot positions Catalyst MedTech to address some of the most pressing challenges facing hospitals and imaging centers today: aging equipment, disruptive technology transitions, and the growing demand for advanced diagnostics. By integrating OEM manufacturing with its established nationwide service network, the company is offering a new kind of partnership—one that promises innovation, longevity, and support through the entire equipment lifecycle.

The Strategic Power of Acquisition

At the heart of Catalyst MedTech's transformation is its acquisition of X3D ApS, a respected Danish engineering firm and OEM formerly known as DDD-Diagnostic. While financial terms were not disclosed, the strategic value is clear. The move provides Catalyst with critical intellectual property, a robust engineering platform with a global install base of approximately 5,000 systems, and—most importantly—the OEM manufacturing capabilities to compete directly with major global medical technology companies.

This is a significant evolution for a company that built its reputation on providing ISO-certified refurbished systems and best-in-class service.

“This acquisition is about far more than adding products,” said Martin Shirley, President & CEO of Catalyst MedTech, in a statement. “It is about strengthening our ability to support thousands of imaging systems already in the field, helping nuclear medicine and molecular imaging departments modernize with confidence, and expanding access to advanced imaging technologies across the country.”

The X3D deal brings two key products into the Catalyst fold: the flagship CorCam™ dedicated cardiac SPECT system, known for its compact footprint and high resolution, and the new QuantumCam™, a flexible, general-purpose nuclear medicine camera. While X3D's Danish engineering hub will continue to drive innovation, manufacturing for the CorCam system is set to transition to the United States, a move expected to strengthen domestic supply chains and production capacity.

A Lifeline for Aging Infrastructure

Catalyst MedTech's announcements come at a critical time for the healthcare industry. Many hospitals and imaging centers are grappling with a fleet of aging diagnostic equipment, creating a cascade of operational and clinical challenges. Compounding this issue are mandatory software and operating system upgrades, such as the transition to Windows 11, which can render older, unsupported systems obsolete and pose significant security risks.

The company is tackling this problem head-on with a multi-pronged modernization strategy. Rather than forcing a complete and costly replacement, Catalyst is offering flexible pathways that include:

• Modernization Pathways: Specific upgrade plans for existing systems to support Windows 11 and other modern software requirements.
• Lifecycle Extension: A suite of services and hardware upgrades designed to extend the operational life of current investments.
• Trade-in and Replacement: Structured programs to help facilities strategically replace outdated or unsupported equipment.

This approach acknowledges the financial and logistical realities faced by many healthcare providers, who must balance reimbursement pressures with the need to manage increasing patient volumes. By offering to upgrade, service, and eventually replace equipment, Catalyst is positioning itself as a long-term partner in managing the entire technology lifecycle.

“At a time when many providers are evaluating how to modernize aging systems, replace unsupported equipment, and plan for the future of molecular imaging, Catalyst MedTech is uniquely positioned to deliver both OEM innovation and nationwide lifecycle support,” Shirley added.

Innovation Across the Imaging Spectrum

Beyond modernization, Catalyst MedTech is significantly expanding its clinical capabilities with a diverse portfolio targeting key areas of nuclear medicine. The company is showcasing a range of new and updated systems at SNMMI Booth #923.

The expanded Digirad® and molecular imaging solutions portfolio now includes:

• QuantumCam™: An ultra-compact, fully flexible general-purpose nuclear medicine camera designed for space-constrained environments, ideal for replacing older small-footprint systems.
• Ergo™: A compact, ergonomic imaging platform engineered for flexible workflows and operational efficiency in nuclear medicine.
• Cardius® Series and X-ACT+®: Advanced cardiac imaging solutions featuring attenuation correction to enhance diagnostic confidence.
• CorCam™: The newly acquired dedicated cardiac SPECT system, engineered for fast, reliable myocardial perfusion imaging.
• CareMiBrain™: An ultra-high-resolution dedicated brain PET platform, exclusively distributed by Catalyst in the United States. It is purpose-built for the growing field of neurologic imaging, including amyloid and tau PET applications for Alzheimer's disease and other neurodegenerative disorders.

In a move demonstrating its commitment to collaborative development, Catalyst is also offering a live technology demonstration of its Ergo+* prototype. This interactive experience allows technologists and clinicians to provide direct feedback on potential future enhancements, such as motorized positioning and a redesigned touchscreen interface. This feedback loop is central to the company's philosophy of customer-driven innovation.

“SNMMI represents an important opportunity for us to collaborate directly with the nuclear medicine community,” Shirley noted. “We want attendees to experience where imaging innovation is heading, share their feedback, and help shape what comes next.”

This strategy—combining in-house OEM innovation, strategic distribution partnerships like the one for CareMiBrain, and a robust modernization program for its existing Digirad® line—creates one of the industry's most comprehensive portfolios. It spans general nuclear medicine, dedicated cardiology, and optimized neurology, all backed by a single, nationwide support infrastructure. This integrated approach aims to provide stability and a clear path forward for customers, regardless of their current technological state or future clinical ambitions.

“Our goal is to become the partner of choice for nuclear medicine and molecular imaging providers nationwide,” Shirley concluded. “Whether customers are evaluating modernization strategies, replacing aging systems, expanding clinical capabilities, or planning for the future of molecular imaging, Catalyst MedTech is building the infrastructure, innovation, and long-term partnerships to help support every stage of that journey.”